Sa

SAMPLE
pl

REPORT
e
 Your Ancestry Composition
Sa
m
pl
e
 e
pl
m
Sa
 ANCESTRY
DEMO ADVANCED
TWJE-DCBA-3565
08:00:05 - 01/04/2022

MIDDLE EAST 0.0

WESTERN ASIAN 0.0

Bedouin 0.0

Morocco - Bedouin 0.0

Egyptian, Levantine and Arab 0.0

Egypt - Egyptian, Levantine and Arab 0.0

Turkish 0.0
Sa
Turkey - Turkish, Caucasian and Iranian 0.0

EUROPE 97.7

EUROPEAN 97.70
m
Greek and Balkan 13.70

Greece - Greek and Balkan 13.7

pl
Basque 14.00

France - Basque 14.0

Italian 0.0
e
Italy - Italian 0.0

French 0.0

France - French 0.0

Iberian 52.50

Spain - Iberian 52.5

Eastern European 0.0

Poland - Eastern European 0.0

Finnish 0.0
 ANCESTRY
DEMO ADVANCED
TWJE-DCBA-3565
08:00:05 - 01/04/2022

Finland - Finnish 0.0

Sardinian 3.70

Sardinia (Italy) - Sardinian 3.7

Scandinavian 8.00

Norway - Scandinavian 8.0

German 0.0

Germany - German 0.0

Sa
Orcadian 0.0

Orkney Islands (United Kingdom) - Orcadian 0.0

British and Irish 0.0

m
United Kingdom - British and Irish 0.0

Ashkenazi Jew 5.80

pl
Germany - Ashkenazi Jew 5.8

AMERICA 0.0
e
NATIVE AMERICAN 0.0

Native American(North) 0.0

United States - Native American (North) 0.0

Native American (Central and South) 0.0

Argentina - Native American (Central and South) 0.0

AFRICA 2.3

AFRICAN 2.30

West African (Nigerian and Ghanaian) 0.0

Ghana - West African (Nigerian and Ghanaian) 0.0

 ANCESTRY
DEMO ADVANCED
TWJE-DCBA-3565
08:00:05 - 01/04/2022

Maghrebi 2.30

Morocco - Maghrebi 2.3

West African (Sierra Leonean and Liberian) 0.0

Liberia - West African (Sierra Leonean and Liberian) 0.0

Pygmy and San hunter-gatherer 0.0

South Africa - Pygmy and San hunter-gatherer 0.0

West African (Gambian and Senegalese) 0.0

Sa
Gambia - West African (Gambian and Senegalese) 0.0

East African (Kenyan and Ugandan) 0.0

Kenya - East African (Kenyan and Ugandan) 0.0

m
EAST ASIA 0.0

EAST ASIAN 0.0

pl
Dai Chinese and Indochinese 0.0

Cambodia - Dai Chinese and Indochinese 0.0

Korean 0.0
e
South Korea - Korean 0.0

Han Chinese 0.0

China - Han Chinese 0.0

Eastern Siberian Natives 0.0

Russia - Eastern Siberian Native 0.0

Siberian Eskimo 0.0

Chukchi Autonomous Okrug (Russia) - Siberian Eskimo 0.0

Japanese 0.0
 ANCESTRY
DEMO ADVANCED
TWJE-DCBA-3565
08:00:05 - 01/04/2022

Japan - Japanese 0.0

Mongolian and NorthChinese 0.0

China - Mongolian and North Chinese 0.0

SOUTH ASIA 0.0

CENTRAL AND SOUTH ASIAN 0.0

Punjabi and Northwest Indian 0.0

Sa
India - Punjabi 0.0

Bengali, Bangladeshi and Northeast Indian 0.0

Bangladesh - Bengali, Bangladeshi and Northeast Indian 0.0

Sri Lankan and Southern Indian 0.0

m
Sri Lanka - Sri Lankan and Southern Indian 0.0

Pakistani and Afghan 0.0

pl
Pakistan - Pakistani and Afghan 0.0

Central Asian 0.0

e
Kazakhstan - Central Asian 0.0

Gujarati Indian 0.0

India - Gujarati Indian 0.0

OCEANIA 0.0

OCEANIAN 0.0

Melanesian 0.0

Solomon Islands - Melanesian 0.0

Papuan 0.0

Papua New Guinea - Papuan 0.0

 Your Wellness

Sa
m
pl
e
 e
pl
m
Sa
 GENERAL REPORT FOR WELLNESS
DEMO ADVANCED
TWJE-DCBA-3565
09:06:52 - 01/04/2022

NAME RESULT

Ability to eliminate harmful substances Slightly reduced

Adipose tissue formation Normal

Antioxidant capacity Slightly reduced

Beta-carotene levels and vitamin A metabolization Slightly increased

Bitter Taste Perception You may perceive the

bitter taste

Blood Glucose 92 mg/dl (average)

Sa
Blood Glucose In Obese Children Increased insulin resistance

Caffeine And Anxiety Normal levels

Caffeine Consumption Increased consume

Caffeine and sports performance Without effect

m
Celiac disease predisposition Not predisposed

Childhood Obesity Measurements Normal

Diet Response Worse response

pl
Exercise-associated muscle cramps Low risk

Exercise-induced muscle damage (initial phase) Probable risk

Exercise-induced muscle damage (regeneration capacity) Usual ability

e
Exercise-induced muscle damage (second phase) Protective effect

Food intake control Typical

Genetic predisposition to peanut allergy Slightly increased

Glucose Tolerance Response With Exercise Typical

HDL Cholesterol Levels Slightly less

Histamine intolerance Slight predisposition to

DAO deficiency and
histamine intolerance

LDL Cholesterol Levels Slightly less

Lactose Intolerance Problably tolerant

Long-chain omega fatty acids levels Decreased

 GENERAL REPORT FOR WELLNESS
DEMO ADVANCED
TWJE-DCBA-3565
09:06:52 - 01/04/2022

Muscle Endurance Probably endurance athlete

Obesity Measurements Increased BMI

Preference For Sweets Increased

Response To Exercise No weight loss with

exercise and reduced
calorie intake

Tendinopathies in lower extremities (legs) Probable risk

Tendinopathies in upper extremities (arms) Probable risk

Vitamin B12 levels Normal

Sa
Vitamin C levels Slightly decreased vitamin
C levels

Vitamin D levels Slightly decreased vitamin

D levels

Vitamin E levels Slightly increased vitamin E

m
levels
pl
e
 Your Traits

Sa
m
pl
e
 GENERAL REPORT FOR TRAITS
DEMO ADVANCED
TWJE-DCBA-3565
09:26:51 - 01/04/2022

NAME RESULT

Aggressive Prostate Cancer Typical risk

Alcohol Addiction Typical alcohol

consumption

Alcohol Flush Reaction Do not show reaction

Asparagus odor detection More likely to be able to

smell asparagus
metabolites in urine

Biological Ageing Slightly reduced

Sa
Birth Weight Slightly increased

Blood Group ABO/Rh Most likely to be blood type

A, Rh-

Blood coagulation, factor V Leiden and 20210G-A Does not have factor V
Leiden and 20210G-A
m
mutations

C-reactive Protein Levels 1,88 mg/L (average)

CCR5Delta32 and susceptibility to HIV infection Typical

pl
Cocaine dependence Increased

Deep sleep Typical

e
Drug Abuse Typical risk

Duffy Antigen (Malaria Resistant) Probably no resistant

Earlobe type Low probability of earlobe

attachment

Earwax type/Armpit odor Likely wet earwax. Habitual

body odor.

Error Avoidance Capacity Increased capacity

Eye Color Probably clear eyes (blue,

green)

Freckles Typical

Gambling behaviour Slightly increased odds of

gambling
 GENERAL REPORT FOR TRAITS
DEMO ADVANCED
TWJE-DCBA-3565
09:26:51 - 01/04/2022

HLA-B27 antigen Absent

Hair Color: Blond Hair Low probability of blond

hair

Hair Color: Red Hair Probably no red hair

Hair Texture Likely to have wavy hair

Hair thinckness Less likely to have thick

hair

Height Tendency to be taller

Heroin Addiction Typical risk

Sa
Intelligence Measurements Normal

Longevity Slightly increased

MTHFR gene Has one copy of A1298C

and one copy of C667T in
MTHFR
m
Malaria Complications Slight protection

Male baldness Increased risk

pl
Memory Slightly reduced

Nasion prominence Low probability of

prominent nasion
e
Nicotine Addiction Typical depence

Nicotine Dependence And Adolescence Less risk

Norovirus resistance Susceptible

PSA (Prostate-specific Antigen) Levels Increased

Pain Sensitivity Increased

Permanent tooth eruption Slightly late eruption

Persistence Of Fetal Hemoglobin Persistent

Photic Sneeze Reflex Absent

Pigmented Rings On The Iris Typical grade

Preterm birth Increased probability

QT Intervals More short

 GENERAL REPORT FOR TRAITS
DEMO ADVANCED
TWJE-DCBA-3565
09:26:51 - 01/04/2022

Secretor status and ABH antigens (FUT2 gene) Secretor

Sex hormone regulation Probably decreased SHBG

levels

Skin pigmentation High likely to have light skin

Sleep movement Likely to move more than

average

Smell, The Sense Of (Olfaction) Perceives floral aroma

Thyroid function Increased TSH levels

Tooth morphology No shovel-shaped incisors

Sa
m
pl
e
 COMPLEX DISEASES

Sa
m
pl
e
 e
pl
m
Sa
 GENERAL REPORT FOR COMPLEX DISEASES
DEMO ADVANCED
TWJE-DCBA-3565
06:40:10 - 18/03/2022

HIGH RISK

NAME YOUR RISK AVERAGE RISK COMPARED TO AVERAGE

Schizophrenia 11.07 % 2.5 % 4.43x

Intracranial aneurysm 2.64 % 2.0 % 1.32x

Ankylosing spondylitis (AS) 1.45 % 1.0 % 1.45x

Coronary heart disease 1.28 % 0.5 % 2.57x

Heart attack 0.99 % 0.5 % 1.97x

Sa
Rheumatoid Arthritis 0.28 % 0.11 % 2.51x

Colorectal cancer 0.02 % < 0.01 % 1.83x

Melanoma 0.02 % < 0.01 % 1.8x

Testicular cancer < 0.01 % < 0.01 % 1.48x

m
Psoriasis 1.38x

Cerebrovascular Accident 1.93x

Thyroid cancer 1.39x

pl
Allergic Asthma 1.55x

Sjögren syndrome 3.0x

e
Priapism in Sickle Cell Anemia 1.61x

Sudden Cardiac Death 1.55x

Hypertriglyceridemia 1.99x

Non-alcoholic fatty liver disease 1.71x

(NAFLD)

Herniated Disc 1.45x

Sarcoidosis 1.4x

Abdominal Aortic Aneurysm 1.28x

Essential tremor 1.22x

 GENERAL REPORT FOR COMPLEX DISEASES
DEMO ADVANCED
TWJE-DCBA-3565
06:40:10 - 18/03/2022

REDUCED RISK

NAME YOUR RISK AVERAGE RISK COMPARED TO AVERAGE

High blood pressure 13.81 % 30.7 % 0.45x

Diabetes Mellitus, Type 2 0.89 % 1.49 % 0.6x

Gout 0.61 % 1.8 % 0.34x

Crohn’s disease 0.03 % 0.2 % 0.14x

Neuroblastoma < 0.01 % < 0.01 % 0.52x

Sa
Diabetes Mellitus, Type 1 < 0.01 % < 0.01 % 0.54x

Macular degeneration, age- < 0.01 % < 0.01 % 0.06x

related

Prostate cancer < 0.01 % < 0.01 % 0.76x

m
Systemic lupus erythematosus < 0.01 % < 0.01 % 0.19x
(SLE)

Multiple sclerosis 0.63x

pl
Lung cancer 0.62x

Osteoarthritis of the knee 0.65x

Primary biliary cirrhosis (PBC) 0.63x

e
Peripheral arterial hypertension 0.65x
disease

Periodontitis 0.72x

Dyslexia 0.63x

Hyperuricemia 0.65x

Chronic obstructive pulmonary 0.44x

disease (COPD)

Grave's disease 0.64x

Vitiligo 0.11x

Fuchs dystrophy 0.25x

Narcolepsy 0.66x
 GENERAL REPORT FOR COMPLEX DISEASES
DEMO ADVANCED
TWJE-DCBA-3565
06:40:10 - 18/03/2022

Craniofacial anomalies (CFA). 0.43x

Cleft lip and/or cleft palate

Exfoliative glaucoma 0.41x

Selective deficiency of IgA 0.72x

Cluster headache 0.66x

Cannabis-induced psychosis 0.78x

Idiopathic membranous 0.54x

nephropathy

Osteoarthritis of the hip 0.65x

Sa
Progressive supranuclear palsy 0.2x
m
pl
e
 GENERAL REPORT FOR COMPLEX DISEASES
DEMO ADVANCED
TWJE-DCBA-3565
06:40:10 - 18/03/2022

TYPICAL RISK

NAME YOUR RISK AVERAGE RISK COMPARED TO AVERAGE

Asthma 4.14 % 4.5 % 0.92x

Bipolar disorder 1.36 % 1.2 % 1.13x

Amyotrophic lateral sclerosis < 0.01 % < 0.01 % 1.01x

Glioma < 0.01 % < 0.01 % 1.04x

Parkinson’s disease < 0.01 % < 0.01 % 1.09x

Sa
Meningioma 0.84x

Bladder cancer 0.95x

Migraine 1.15x

Depression 0.84x
m
Hypothyroidism 0.83x

Atrial fibrillation 1.06x

Autism 0.89x
pl
Ulcerative colitis 0.84x

Deep vein thrombosis 0.91x

e
Non-Hodgkin’s lymphoma 0.93x

Pulmonary Fibrosis 0.96x

Basal cell carcinoma 0.84x

Cataracts 0.99x

Chronic lymphocytic leukemia 0.88x

Osteoporosis 0.99x

Pancreatic cancer 0.85x

Primary open-angle glaucoma 1.11x

Seasonal affective disorder 0.9x

Biliary calculus or gallstones 0.9x

Chronic kidney disease 0.9x

 GENERAL REPORT FOR COMPLEX DISEASES
DEMO ADVANCED
TWJE-DCBA-3565
06:40:10 - 18/03/2022

Eosinophilic esophagitis (EoE) 0.98x

Myasthenia gravis 1.18x

Multiple myeloma 0.84x

Atopic dermatitis or eczema 0.87x

Esophageal Cancer 0.98x

Glioblastoma 1.05x

Oral and throat cancer 1.06x

Sa
m
pl
e
 Your PHARMACOLOGY

Sa
m
pl
e
 e
pl
m
Sa
 GENERAL REPORT FOR DRUGS
DEMO ADVANCED
TWJE-DCBA-3565
06:42:19 - 18/03/2022

NAME RESULT

Amifampridina (Dosage) Intermediate metabolizer

Amitriptyline (Dosage) CYP2D6 Intermediate

metabolizer/CYP2C19
Normal metabolizer

Arformoterol (Efficacy) CYP2D6 Intermediate

metabolizer/UGT1A1
Intermediate metabolizer
(Poor Metabolizer)

Aripiprazole (Dosage) Intermediate metabolizer

Sa
Atomoxetine (Dosage) Intermediate metabolizer.
May present side effects

Brexpiprazole (Dosage) Intermediate metabolizer

Carbamazepine (Dosage) Ultrarapid metabolizer

m
Clomipramine (Dosage) CYP2D6 Intermediate
metabolizer/CYP2C19
Normal metabolizer

Clozapine (Dosage) Intermediate metabolizer

pl
Codeine (Dosage) Intermediate metabolizer

Cyclophosphamide, Fluorouracil, Methotrexate (Efficacy) Probably diminished

e
response

Cyclosporine (Dosage) Poor metabolizer

Desipramine (Dosage) Intermediate metabolizer

Disulfiram (Efficacy) Sensitive to disulfiram

Eliglustat (Dosage) Intermediate metabolizer.

Standard dose: 2 doses of
84 mg per day

Fesoterodine (Dosage) Intermediate metabolizer

Flecainide (Dosage) Intermediate metabolizer.

Dose reduction by 25%

Fluoxetine (Efficacy) Intermediate metabolizer

Fluvoxamine (Dosage) Intermediate metabolizer

Due to the importance of the information provided in this report, we recommend contacting a professional. 1
TellmeGen has professionals capable of providing genetic advice through its platform.
 GENERAL REPORT FOR DRUGS
DEMO ADVANCED
TWJE-DCBA-3565
06:42:19 - 18/03/2022

Haloperidol (Dosage) Intermediate metabolizer

Iloperidone (Dosage) Intermediate metabolizer

Methotrexate in Rheumatoid Arthritis (Adverse effects) Slightly increased risk of

adverse effects

Methotrexate in rheumatoid arthritis (Efficacy) Inefficient response

Metoprolol (Dosage) Intermediate metabolizer

Nortriptyline (Dosage) Intermediate metabolizer

Paroxetin (Dosage) Intermediate metabolizer

Sa
Perphenazine (Dosage) Intermediate metabolizer

Pimozide (Dosage) Intermediate metabolizer

Pravastatin (Efficacy) Probably does not respond

adequately to pravastatin

Propranolol (Efficacy) Intermediate metabolizer

m
Risperidone (Dosage) Intermediate metabolizer

Tramadol (Dosage) Intermediate metabolizer

Valproic Acid (Adverse effects) Increased risk of liver

pl
toxicity

Venlafaxine (Dosage) Intermediate metabolizer

Zuclopenthixol (Dosage) Intermediate metabolizer

e
Abacavir (Adverse effects) No expected variations

Acenocoumarol, Phenprocoumon (Dosage) Normal or extensive

metabolizer

Acetaldehyde (Adverse effects) No expected variations

Atazanavir, Ritornavir (Interaction) Normal or extensive

metabolizer for
voriconazole. Usual
interactions.

Brivaracetam (Dosage) Normal or extensive

metabolizer

Celecoxib (Dosage) Normal or extensive

metabolizer
 GENERAL REPORT FOR DRUGS
DEMO ADVANCED
TWJE-DCBA-3565
06:42:19 - 18/03/2022

Citalopram (Dosage) Normal or extensive

metabolizer

Clopidogrel (Dosage) Normal or extensive

metabolizer

Diazepam (Efficacy) Normal or extensive

metabolizer

Erythromycin/Sulfisoxazole (Adverse effects) No risk

Escitalopram (Dosage) Normal or extensive

metabolizer

Esomeprazole (Efficacy) Normal or extensive

Sa
metabolizer

Fluorouracil (Adverse effects) No expected variations

Fluorouracil, Capecitabine, Tegafur (Adverse effects) Normal or extensive

metabolizer
m
Glipizide (Dosage) Normal or extensive
metabolizer

Irinotecan (Adverse effects) Read technical report

pl
Ivacaftor (Efficacy) Does not present the
disease

Lansoprazole (Dosage) Normal or extensive

metabolizer
e
Lorazepam (Efficacy) Intermediate metabolizer

Mercaptopurine (Dosage) Normal or extensive

metabolizer

Mipomersen (Efficacy) No symptoms

Omeprazole (Efficacy) Normal or extensive

metabolizer

Oral antidiabetic drugs sulfonylureas (Dosage) No expected variations

Pantoprazole (Efficacy) Normal or extensive

metabolizer

Pegylated interferon alfa + Ribavirin / Bocepevir (Efficacy) Read technical report

Phenytoin (Dosage) Normal or extensive

metabolizer
 GENERAL REPORT FOR DRUGS
DEMO ADVANCED
TWJE-DCBA-3565
06:42:19 - 18/03/2022

Phenytoin (Efficacy) No expected variations

Prasugrel (Dosage) Normal or extensive

metabolizer

Prasugrel, Ticagrelor, Clopidogrel (Efficacy) Normal or extensive

metabolizer

Pseudocholinesterase (Interaction) Read technical report

Rabeprazole (Efficacy) Normal or extensive

metabolizer

Sertraline (Dosage) Normal or extensive

metabolizer
Sa
Statins (Adverse effects) No expected variations

Tacrolimus (Dosage) Poor metabolizer

Thioguanine, Azathioprine, Mercaptopurine (Dosage) No expected variations

Ticagrelor (Dosage) Normal or extensive

m
metabolizer

Voriconazole (Dosage) Normal or extensive

metabolizer
pl
Warfarin (Dosage) Normal or extensive
metabolizer

Acetylsalicylic Acid (ASA) (Adverse effects) Increased risk

e
Acetylsalicylic Acid (ASA) in cardiovascular events prevention (Efficacy) No expected variations

Acetylsalicylic acid (ASA) in colorectal cancer prevention (Efficacy) Chemoprophylaxis with

Aspirin may be beneficial

Amitriptyline (Adverse effects) CYP2D6 Intermediate

Metabolizer (Decrease
Dose)/ CYP2C19 Normal
Metabolizer

Antidepressants (Efficacy) Very high input level of

antidepressant to the brain
(very high response to
antidepressants, caution in
the dose)

Atazanavir (Adverse effects) PM for UGT1A1, high

probability of developing
 GENERAL REPORT FOR DRUGS
DEMO ADVANCED
TWJE-DCBA-3565
06:42:19 - 18/03/2022

hyperbilirubinemia

Cabozantinib (Efficacy) Does not respond to

treatment

Caffeine (Adverse effects) Poor metabolizer

Calcium channel blockers and diuretics (Efficacy) It is better to treat with

calcium channel blockers
drugs

Chlorthalidone (Efficacy) Better response

Cisplatin (Efficacy) Read technical report

Sa
Donepezil, Galantamine (Dosage) Read technical report

Fentanyl (Efficacy) Poor metabolizer

Gemcitabine in pancreatic cancer treatment (Efficacy) Good response

General anesthetics (Adverse effects) Increased risk of

postoperative nausea and
m
vomiting

Glimepiride, Glyburide, Gliclazide (Efficacy) Normal or extensive

metabolizer
pl
Inhaled corticosteroids (Efficacy) Read technical report

Metformin (Efficacy) Inefficient response

Metoprolol, Carvedilol, Propranolol (Efficacy) Increased response

e
Olaparib (Efficacy) Does not respond to
olaparib

Oral antidiabetic drugs sulfonylureas (Efficacy) Usual response

Paclitaxel (Dosage) Intermediate metabolizer

(significantly increased
toxicity)

Paclitaxel in solid tumour treatment (Adverse effects) Usual neuropathy risk

Palonosetron (Efficacy) Intermediate metabolizer

Risperidone (Efficacy) Responds better than usual

to risperidone

Tamoxifen (Efficacy) Intermediate metabolizer

Tolbutamide (Efficacy) Normal or extensive

 GENERAL REPORT FOR DRUGS
DEMO ADVANCED
TWJE-DCBA-3565
06:42:19 - 18/03/2022

metabolizer

Ziprasidone (Efficacy) Low response to

ziprasidone

Acenocoumarol, Phenprocoumon (Efficacy) Significantly increased

response. Dose adjustment
is recommended

Atenolol (Efficacy) Decreased response

Bevacizumab (Efficacy) Increased response

Bleomycin (Efficacy) No expected variations

Sa
Bupropion in smoking cessation (Efficacy) Bupropion is more efficient

Carbamazepine (Adverse effects) No expected variations

Carisoprodol (Adverse effects) Normal or extensive

metabolizer

Clobazam (Efficacy) Normal or extensive

m
metabolizer

Cyclophosphamide, Fluorouracil, Methotrexate (Adverse effects) Side effects more

numerous than the usual
pl
Duloxetina (Efficacy) Slightly better than normal
response to duloxetine

Floxacillin (Adverse effects) No expected variations

e
Fluoxetine, Citalopram, Escitalopram (Efficacy) Increased response

Furosemide, Torasemide (Efficacy) Usual response

Gabapentin (Efficacy) Probably increased

efficacy, decrease dose to
avoid adverse effects

Gefitinib (Adverse effects) No expected variations

Gonadotrophins and Ovulation Stimulants (Efficacy) Probably ineffective

response

Hydrochlorothiazide (Efficacy) Better response

Iloperidone (Adverse effects) Probable risk of QT interval

prolongation

Imatinib (Efficacy) Respond to treatment

 GENERAL REPORT FOR DRUGS
DEMO ADVANCED
TWJE-DCBA-3565
06:42:19 - 18/03/2022

Lithium (Efficacy) Effective response

Lumacaftor + Ivacaftor (Efficacy) It does not present the

deletion. Treatment not
recommended

Methotrexate in chemotherapy (Adverse effects) Slightly increased risk of

adverse effects

Methotrexate in transplant rejection (Efficacy) Increased risk of rejection

Methylphenidate (Efficacy) Probably poor response

Mirtazapine (Efficacy) Increased response

Sa
Morphine, Oxycodone, Fentanyl (Dosage) Increased response

Naltrexone (Efficacy) No expected variations

Nelfinavir (Efficacy) Normal or extensive

metabolizer

Olanzapine (Adverse effects) Much more likely

m
Paclitaxel (Efficacy) Usual response

Paracetamol (Efficacy) Likely adequate or

acceptable response
pl
Risperidone (Adverse effects) Much more likely

Rosiglitazone (Efficacy) Increased response to

Rosiglitazone
e
Simvastatin (Dosage) Normal or extensive
metabolizer

Trastuzumab (Efficacy) No expected variations

Triptans (Efficacy) Likely good efficacy

Venlafaxine (Efficay) Elevated response to

venlafaxine

Vincristine (Efficacy) Decreased relapse risk

Warfarin (Efficacy) Highly increased sensitivity

to warfarin

Acetylcholinesterase Inhibitors Galantamine, Donepezil, Rivastigmine (Efficacy) Decreased response

Acetylsalicylic Acid (ASA) (Efficacy) No expected variations

 GENERAL REPORT FOR DRUGS
DEMO ADVANCED
TWJE-DCBA-3565
06:42:19 - 18/03/2022

Alfentanil (Efficacy) Efficient response

Amisulpride, Aripiprazole, Clozapine, Olanzapine, Haloperidol, Quetiapine, Slight increased risk of

Risperidone, Ziprasidone, Palperidone (Adverse effects) weight-gain

Bisoprolol (Efficacy) Efficient response

Bupropion (Adverse effects) Common side effects

Carvedilol (Dosage) Intermediate metabolizer

Corticosteroids + B2 Agonists (Efficacy) Better response

Docetaxel (Adverse effects) Less risk

Sa
Gemcitabine (Adverse effects) Probability of toxicity

Gemcitabine in breast cancer treatment (Efficacy) Good response

Gemcitabine in non-small cell lung cancer treatment (Efficacy) Ineffective response

Gemcitabine in the treatment of malignant mesiotheloma (Efficacy) Good response

Iloperidone (Efficacy) Decreased response

m
Methadone (Dosage) Higher dose of Methadone

Montelukast (Dosage) Fast metabolizer

pl
Montelukast (Efficacy) Decreased response

Morphine (Adverse effects) Usual risk of side effects

Nelfinavir on lymphocytes count (Efficacy) Usual response

e
Olanzapine (Efficacy) No expected variations

Paclitaxel in ovarian cancer treatment (Adverse effects) Hematotoxicity risk slightly

increased

Quetiapine (Dosage) Normal or extensive

metabolizer

Selective Serotonin Reuptake Inhibitors (SSRIs) (Adverse effects) No expected variations

Sildenafil (Viagra) Response Usual response

Vaccination (Adverse effects) Some possibility of adverse

reaction

Vincristine (Adverse effects) Protective effect against

side effects

Vincristine (Dosage) Poor metabolizer

 GENERAL REPORT FOR DRUGS
DEMO ADVANCED
TWJE-DCBA-3565
06:42:19 - 18/03/2022

Voriconazole (Adverse effects) Increased plasma levels

Sa
m
pl
e
 MONOGENIC DISEASES

Sa
m
pl
e
 e
pl
m
Sa
 GENERAL REPORT FOR MONOGENIC DISEASES
DEMO ADVANCED
TWJE-DCBA-3565
06:41:46 - 18/03/2022

NAME RESULT

Hereditary hemochromatosis associated with HFE Variant present

ARSACS (Autosomal recessive spastic ataxia of Charlevoix-Saguenay) Variant absent

Acute intermittent porphyria Variant absent

Agenesis of the Corpus Callosum with Peripheral Neuropathy (ACCPN) Variant absent

Alpha-1 Antitrypsin Deficiency Variant absent

Alpha-mannosidosis Variant absent

Autosomal recessive polycystic kidney disease Variant absent

Sa
Beta Thalassemia Variant absent

Biotinidase deficiency Variant absent

Birt-Hogg-Dube syndrome Variant absent

Bloom syndrome Variant absent

m
Brugada Syndrome Variant absent

Canavan Disease Variant absent

Classical homocystinuria due to CBS deficiency Variant absent

pl
Complete achromatopsia (type 2) and Incomplete achromatopsia Variant absent

Congenital disorder of glycosylation type 1a (PMM2-CDG) Variant absent

e
Congenital muscular -dystroglycanopathy and Walker-Warburg syndrome Variant absent

Congenital myasthenic syndrome Variant absent

Congenital stationary night blindness 1C Variant absent

Cystic fibrosis Variant absent

Cystinosis Variant absent

D-Bifunctional Protein Deficiency Variant absent

Diastrophic dysplasia Variant absent

Dihydrolipoamide Dehydrogenase Deficiency Variant absent

Dilated Cardiomyopathy 1A Variant absent

Dubin-Johnson syndrome Variant absent

Ehlers-Danlos Syndrome (EDS) Variant absent

 GENERAL REPORT FOR MONOGENIC DISEASES
DEMO ADVANCED
TWJE-DCBA-3565
06:41:46 - 18/03/2022

Familial Hypercholesterolemia Variant absent

Familial Hypertrophic Cardiomyopathy (HCM) Variant absent

Familial Mediterranean fever Variant absent

Familial Transthyretin Amyloidosis Variant absent

Familial adenomatous polyposis Variant absent

Familial advanced sleep phase disorder (FASPS) Variant absent

Familial dysautonomia (Riley-Day syndrome) Variant absent

Familiar hyperinsulinism (ABCC8-related) Variant absent

Sa
Fanconi Anemia (FANCC-related) Variant absent

GRACILE syndrome Variant absent

Gaucher disease Variant absent

Glucose-6-phosphate dehydrogenase deficiency(G6PD deficiency) Variant absent

m
Glutaric Acidemia type 1 Variant absent

Glutaric Acidemia type 2 Variant absent

Glycogen storage disease type 1A (Von Gierke Disease) Variant absent

pl
Glycogen storage disease type 1B Variant absent

Glycogen storage disease type 2 or Pompe Disease 1 & 2 Variant absent

Glycogen storage disease type 3 Variant absent

e
Glycogen storage disease type 5 Variant absent

Hemophilia A Variant absent

Hereditary fructose intolerance Variant absent

Homocystinuria due to MTHFR deficiency Variant absent

Hypokalemic Periodic Paralysis Variant absent

Hypophosphatasia Variant absent

Junctional Epidermolysis Bullosa Variant absent

Leigh Syndrome, French-Canadian type (LSFC) Variant absent

Leukoencephalopathy with vanishing white matter Variant absent

Li-Fraumeni Syndrome Variant absent

 GENERAL REPORT FOR MONOGENIC DISEASES
DEMO ADVANCED
TWJE-DCBA-3565
06:41:46 - 18/03/2022

Limb-girdle muscular dystrophy Variant absent

Malignant Hyperthermia Variant absent

Maple syrup urine disease type 1B Variant absent

Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) Variant absent

Metachromatic leukodystrophy Variant absent

Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency Variant absent

Mucolipidosis IV Variant absent

Mucolipidosis type II Variant absent

Sa
Multiple endocrine neoplasia 2B Variant absent

Neuronal Ceroid-Lipofuscinoses type 1 (associated to PPT1) Variant absent

Neuronal Ceroid-Lipofuscinoses type 3 (associated to CLN3) Variant absent

Neuronal Ceroid-Lipofuscinoses type 5 (associated to CLN5) Variant absent

m
Neuronal Ceroid-Lipofuscinoses type 6 (associated to CLN6) Variant absent

Neuronal Ceroid-Lipofuscinoses type 7 (associated to MFSD8) Variant absent

Niemann-Pick disease type A Variant absent

pl
Non-syndromic mitochondrial hearing loss Variant absent

Nonsyndromic Hearing Loss and Deafness, DFNB1 Variant absent

Pendred syndrome Variant absent

e
Peters plus syndrome Variant absent

Phenylketonuria Variant absent

Pontocerebellar hypoplasia Variant absent

Primary hyperoxaluria type 1 (PH1) Variant absent

Primary hyperoxaluria type 2 (PH2) Variant absent

Pyridoxine-dependent epilepsy Variant absent

Refsum disease Variant absent

Retinitis pigmentosa Variant absent

Rhizomelic Chondrodysplasia Punctata Type 1 Variant absent

Salla Disease Variant absent

 GENERAL REPORT FOR MONOGENIC DISEASES
DEMO ADVANCED
TWJE-DCBA-3565
06:41:46 - 18/03/2022

Short chain acyl-CoA dehydrogenase deficiency (SCADD) Variant absent

Sjögren-Larsson syndrome Variant absent

Spinal muscular atrophy Variant absent

Tay-Sachs disease Variant absent

Type 1 Oculocutaneous albinism (tyrosinase negative) Variant absent

Type 2 oculocutaneous albinism (tyrosinase positive) Variant absent

Tyrosinemia type I Variant absent

Usher syndrome Variant absent

Sa
Very long chain acyl-CoA dehydrogenase deficiency (VLCADD) Variant absent

Wilson disease Variant absent

Zellweger syndrome Variant absent

cblA Type Methylmalonic aciduria Variant absent

m
cblB Type Methylmalonic aciduria Variant absent
pl
e